XOLAIR Drug Profile

Summary for Tradename: XOLAIR

High Confidence Patents:	20
Applicants:	1
BLAs:	1
Recent Clinical Trials:	See clinical trials for XOLAIR

Recent Clinical Trials for XOLAIR

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Taizhou Mabtech Pharmaceutical Co.,Ltd	PHASE3
University of California, Davis	Phase 3
Kashiv BioSciences, LLC	Phase 3

See all XOLAIR clinical trials

Pharmacology for XOLAIR

Mechanism of Action	IgE-directed Antibody Interactions
Physiological Effect	Decreased IgE Activity
Established Pharmacologic Class	Anti-IgE

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and company disclosures

These patents were identified from searching various sources, including drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for XOLAIR Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for XOLAIR Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	XOLAIR	omalizumab	For Injection	103976	10,300,185	2038-10-05	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	XOLAIR	omalizumab	For Injection	103976	10,300,186	2038-10-12	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	XOLAIR	omalizumab	For Injection	103976	10,561,756	2037-05-01	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	XOLAIR	omalizumab	For Injection	103976	10,561,757	2037-05-01	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	XOLAIR	omalizumab	For Injection	103976	10,561,758	2038-04-23	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	XOLAIR	omalizumab	For Injection	103976	10,603,444	2035-08-28	DrugPatentWatch analysis and company disclosures
Genentech, Inc.	XOLAIR	omalizumab	For Injection	103976	10,603,445	2037-06-07	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for XOLAIR Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Genentech, Inc.	XOLAIR	omalizumab	For Injection	103976	10,011,584	2035-05-01	Patent claims search
Genentech, Inc.	XOLAIR	omalizumab	For Injection	103976	10,016,338	2036-12-20	Patent claims search
Genentech, Inc.	XOLAIR	omalizumab	For Injection	103976	10,028,940	2037-03-16	Patent claims search
Genentech, Inc.	XOLAIR	omalizumab	For Injection	103976	10,086,076	2037-03-13	Patent claims search
Genentech, Inc.	XOLAIR	omalizumab	For Injection	103976	10,111,968	2036-08-10	Patent claims search
Genentech, Inc.	XOLAIR	omalizumab	For Injection	103976	10,182,561	2036-06-14	Patent claims search
Genentech, Inc.	XOLAIR	omalizumab	For Injection	103976	10,184,001	2036-06-02	Patent claims search

International Patents for XOLAIR

Country	Patent Number	Estimated Expiration
Japan	2024097028
World Intellectual Property Organization (WIPO)	2012024659
Hong Kong	1197252
China	1646563
Japan	2010239970
Mexico	2007009060
United Kingdom	0002930

Supplementary Protection Certificates for XOLAIR

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
SZ 6/2006	Austria		PRODUCT NAME: OMALIZUMAB
SPC/GB06/006	United Kingdom		PRODUCT NAME: OMALIZUMAB AND ITS PHARMACEUTICALLY ACCEPTABLE FORMS; REGISTERED: UK EU/1/05/319/001 20051024; UK EU/1/05/319/002 20051024
6/2006	Austria		PRODUCT NAME: OMALIZUMAB; REGISTRATION NO/DATE: EU/1/05//319/001 UND002 20051025
C300222	Netherlands		PRODUCT NAME: OMALIZUMAB; REGISTRATION NO/DATE: EU/1/05/319/001- EU/1/05/319/002 20051025
06C0006	France		PRODUCT NAME: OMALIZUMAB ET SES FORMES PHARMACEUTIQUEMENT ACCEPTABLES; REGISTRATION NO/DATE IN FRANCE: EU/1/05/319/001 DU 20051025; REGISTRATION NO/DATE AT EEC: E/1/05/319/001 DU 20051025

XOLAIR: Market Dynamics and Financial Trajectory for the Biologic

Last updated: April 23, 2026

XOLAIR (omalizumab) remains a high-value, multi-indication biologic with revenue driven by chronic use, pricing power, and expanding patient addressability in allergic asthma, chronic spontaneous urticaria (CSU), and related allergic conditions. Financial trajectory is shaped by (1) disease-management intensity (every-2- and every-4-week dosing), (2) biosimilar/regional competition risks versus claims of clinical differentiation, and (3) payer contracting cycles tied to biologic utilization and step-therapy protocols. The market is concentrated in large administered-care channels and specialty pharmacies, with uptake influenced by guideline adherence and payer authorization criteria.

How big is the XOLAIR market opportunity by indication?

XOLAIR is marketed for multiple allergic or immune-mediated indications that share a common dosing mechanic (weight- and IgE-based for asthma; fixed dosing for other indications depending on labeling). This multi-indication structure reduces dependence on any single submarket and helps stabilize demand through patient switching within payer formularies.

Core labeled use (high-level market relevance)

• Moderate-to-severe allergic asthma (in appropriate patients)
• Chronic spontaneous urticaria (CSU)

These indications drive recurring utilization and support long-duration patient cohorts relative to short-course therapies. XOLAIR’s asthma positioning also benefits from the continuing need for biologics that reduce exacerbations and steroid dependence in eligible patient segments, which payers evaluate using health-economic models tied to hospitalization and oral corticosteroid reduction.

What market dynamics influence XOLAIR demand and pricing power?

Dosing cadence creates durable demand

XOLAIR is typically dosed on an ongoing basis, with administration intervals that sustain treatment continuity. This dosing cadence supports revenue durability versus therapies that rely on episodic treatment windows.

Payer controls drive utilization but also lock in treated cohorts

Specialty pharmacy and payer authorization requirements strongly influence:

• how quickly eligible patients enter treatment,
• whether patients remain on therapy after initial response criteria,
• dose and frequency adherence under prior authorization rules.

Once a cohort is established, payer policies often shift from “entry gates” to “continuation gates,” using response metrics that favor ongoing biologic therapy in responders.

Guidelines and clinical practice affect penetration

Asthma and urticaria treatment algorithms influence biologic uptake. When guidelines favor biologics in specific subpopulations, market penetration expands through:

• increased referrals to specialists,
• structured assessment of eligibility criteria,
• periodic adoption cycles after outcomes and safety data become standard in prescribing practice.

Competition risk is measured by formulary placement, not just molecules

XOLAIR competes against other biologics in overlapping patient populations. Real-world dynamics depend on:

• formulary tier and prior authorization burden,
• net pricing after rebates and pharmacy benefit manager contracting,
• clinical differentiation claims (response speed, durability, steroid-sparing),
• availability and administration channel (infusion versus injection workflows).

What is the financial trajectory for XOLAIR (revenue drivers and inflection points)?

Revenue drivers

XOLAIR financial performance is driven by:

• Patient persistence and churn control: continuity in chronic indications.
• Net price realization: contract structure, rebate intensity, and substitution risk.
• Indication mix: relative growth in CSU versus allergic asthma cohorts changes growth rate due to different patient pool sizes and payer behaviors.
• Geography and payer mix: administered-care economics vary by country and health system.

Typical trajectory pattern in mature biologics

For biologics at XOLAIR’s maturity level, the trajectory generally shows:

• steady base growth or modest decline when patient numbers are stable but pricing pressure rises,
• stepwise changes when payer formularies or competitor offerings shift,
• episodic inflections when new label expansions or clinical practice patterns alter eligibility.

How does biosimilar and class competition affect XOLAIR economics?

Biosimilar pressure in the biologic class can reduce price realization through:

• formulary substitution,
• tightened payer criteria requiring stronger outcome evidence,
• increased rebate demands to maintain preferred status.

For XOLAIR specifically, the more binding constraint tends to be payer contracting rather than wholesale market exits. Even where multiple biologics exist, brand leaders often retain market share through:

• demonstrated clinical performance in payer-relevant endpoints (exacerbations, itch/control measures, steroid reduction),
• established patient familiarity and prescriber confidence,
• payer comfort with predictable dosing and monitoring workflows.

What is the expected financial impact from payer contracting dynamics?

In biologics, net revenue swings are often more sensitive to:

• rebate rate changes after competitor entry or formulary renegotiation,
• restriction creep in authorization rules (step therapy, biomarker thresholds),
• channel shifts between specialty pharmacy and provider-administered settings.

For XOLAIR, ongoing chronic use means that payer changes can be high-impact:

• Switching at initiation reduces new starts quickly.
• Discontinuation incentives can increase churn if continuation criteria become strict.
• Continuation criteria tightening may not immediately remove existing patients but can slow future cohort expansion.

What should investors and R&D leaders watch in XOLAIR financial reporting?

Key readouts for XOLAIR trajectory:

1. Global and segment sales growth rate: watch for sustained growth versus stepwise deceleration.
2. Demand indicators by major geography: shifts in payer pressure show up as margin and net price changes.
3. Channel mix: growth in provider-administered versus specialty pharmacy can alter net revenue realization.
4. Formulary outcomes: preferred status renewals versus re-tiering.
5. Indication mix changes: any sustained growth in CSU can buffer asthma-specific category pressures.

What are the practical implications for business strategy?

Commercial strategy

• Maintain preferred payer positioning via continuation-value arguments tied to reductions in exacerbations, healthcare utilization, and symptom control.
• Target patient initiation pathways that align with payer authorization criteria to reduce friction costs for new starts.

R&D strategy

• Focus on label-relevant endpoints that are directly used in payer response criteria.
• Design trials that support continuation rather than only initial response, because persistence is central to mature biologics revenue economics.

Key Takeaways

• XOLAIR’s market is driven by chronic, recurring dosing in allergic asthma and CSU, supporting durable demand relative to episodic therapies.
• Pricing power is constrained by payer contracting cycles and rebate dynamics, not just molecule-level competition.
• Competitive impact typically shows up as formulary placement changes and tighter prior authorization/continuation criteria that affect initiation and persistence.
• The most decision-relevant signals for trajectory are net pricing realization, cohort persistence, indication mix, and channel/geography sales dynamics.

FAQs

1) What drives XOLAIR revenue most strongly?
Patient persistence in chronic indications and net price realization after payer contracting.

2) How do payer authorization rules affect XOLAIR performance?
They influence the number of eligible new starts and can later tighten continuation criteria, affecting churn and cohort growth.

3) What role does indication mix play in XOLAIR trajectory?
Shifts between allergic asthma and CSU can change growth rates because patient pools and payer behaviors differ by indication.

4) How does competition show up in financials for mature biologics like XOLAIR?
Through formulary re-tiering, higher rebates, and restriction creep in authorization rather than sudden market exits.

5) What should R&D teams optimize for to protect revenue in the long run?
Endpoints that support payer continuation decisions and long-term clinical durability, not only initial response.

---

References

[1] Novartis. Xolair (omalizumab) prescribing information.
[2] FDA. Xolair (omalizumab) product label and regulatory history.
[3] GlobalData. Biologic drug market overview: asthma and urticaria biologics (market and competitive landscape reports).
[4] EMA. Xolair (omalizumab) EPAR and authorized indications.